CCN2
CCN family member 2
As of the edition of 20 October 2026, CCN2 (CCN family member 2, UniProt P29279) has 5 drugs tested at it and 5 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P29279
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Disease areas
- Lungs and airways; Hormones; Cancer; Digestive system; Bones, joints and muscles; Inherited and neonatal; Nervous system; Nutrition and metabolism
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 2 |
| Status not established | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pamrevlumab | Stopped | Phase 3 | none listed |
| OLX10010 | Active | Phase 2 | none listed |
| PF-06473871 | Stopped | Phase 2 | none listed |
| PRS-220 | Status not established | Phase 1 | none listed |
| SHR-1906 | Status not established | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Kyntra Bio | Route A |
| Pfizer | Route A |
The other 3 companies at CCN2
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at CCN2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.